Login
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC

anaptysbio.com

What Do They Do?

Manages pharmaceutical collaborations for antibody medicines used in cancer and inflammatory diseases.

How Do They Make Money?

Receives royalties and milestone payments tied to Jemperli under the GSK collaboration. Vanda paid an upfront license fee and drug-supply payment for imsidolimab; Anaptys may also receive sales royalties and milestone payments, plus license and transition-service revenue.

revenue
SegmentShareRevenue
Biopharma
0.0%
Royalty Management
100%

Who Are Their Customers?

Pharmaceutical partners GSK and Vanda contract with Anaptys through collaborations and licenses; Vanda holds an exclusive global license for imsidolimab.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q1 FY2027, the three months to Sep 30, 2026
Revenue
▼ −60%
vs $76.3M in Q1 FY2026
Net income
▼ −74%
vs $15.1M in Q1 FY2026
Royalty Management share of revenue
  • May 11, 2026 Anaptys appointed Christopher M. Murphy as CFO
  • Apr 20, 2026 Anaptys completed the First Tracks Biotherapeutics spin-off It now exclusively manages financial collaborations for Jemperli and imsidolimab.
  • Mar 26, 2026 Board approved the First Tracks Biotherapeutics spin-off First Tracks was set to launch with $180 million in cash, including $80 million from a private placement.

Growing. Revenue grew 3.7x in 4 years, from $63.2M in FY2021 to $234.6M in FY2025, about 39% a year.

Imsidolimab licensing The earlier report said Anaptys was exploring an out-license for imsidolimab; the newer report says it granted Vanda an exclusive global license and earned license and transition-service revenue from the collaboration.

Revenue over time
Biopharma Royalty Management
$250M$125M$0

Who Do They Compete With?

Competes with Gilead, Seismic Therapeutics, Abbvie, Roche, Regeneron, BMS, Eli Lilly, Pfizer, Forte Bioscience, Novartis, Teva, Biogen, Dianthus Therapeutics, and Amgen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support